To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00255372
Recruitment Status : Completed
First Posted : November 18, 2005
Last Update Posted : June 4, 2008
Information provided by:

Brief Summary:
The purpose of this study is to determine whether Forlax® is more effective than placebo in relieving chronic constipation in children who may also suffer from soiling or faecal incontinence.

Condition or disease Intervention/treatment Phase
Chronic Constipation Drug: PEG 4000 (Forlax®) Drug: Lactulose active and Lactulose placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Polyethylene Glycol Laxative (Macrogol 4000;Forlax®) for Treatment of Chronic Constipation in Children : A Phase III, Bicentric, Randomized, Double-Blind, Lactulose Controlled Study.
Study Start Date : April 2005
Primary Completion Date : May 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Lactulose
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: PEG 4000 (Forlax®)
Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
Active Comparator: 2 Drug: Lactulose active and Lactulose placebo
Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.

Primary Outcome Measures :
  1. Bowel movement frequency [ Time Frame: week 4 ]

Secondary Outcome Measures :
  1. Subjective symptoms associated with defecation. [ Time Frame: At every visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Months to 36 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic constipation (defined as at least 3 months of less than 2 bowel movements (BMs) per week and/or one of the following symptoms : hard stool, painful defecation, encopresis)
  • Constipation previously treated by dietary advice (high fiber diet) for at least two weeks without efficacy

Exclusion Criteria:

  • Organic bowel diseases
  • Suspected GI obstruction
  • History of GI surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00255372

Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand, 10400
Maharat Nakhon Ratchasima Hospital
Nakhon Ratchasima, Thailand, 30000
Sponsors and Collaborators
Study Director: Axel Magis, MD Ipsen

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Axel Magis MD, Ipsen Identifier: NCT00255372     History of Changes
Other Study ID Numbers: A-38-52072-012
First Posted: November 18, 2005    Key Record Dates
Last Update Posted: June 4, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Gastrointestinal Agents